Latest News and Press Releases
Want to stay updated on the latest news?
-
Abivax annonce la fixation du prix de l’Offre au public largement sursouscrite de 800 M$ (702 M€) d’American Depositary Shares Le montant de l'offre a été augmenté de 600 M$ à 800 M$, à un prix de...
-
New preclinical data will guide antigen selection for a broadly protective cytomegalovirus vaccine candidatePoster presentation on July 12, 2026, at the International Herpesvirus Workshop 2026 taking...
-
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...
-
-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- BRISBANE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the...
-
WEST PALM BEACH, FLORIDA, July 01, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXO) (“FOXO” or the “Company”), today announced that its previously approved reverse stock split (the...
-
CLEVELAND, July 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...
-
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...
-
Neil Gallagher, MD, PhD, joins with over 25 years clinical development experience, having contributed to multiple commercial therapeutics across haematology and oncologyHis appointment will strengthen...
-
Secures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Program Ebstrocel for Epidermolysis Bullosa and Next-Generation Engineered Modalities Extending to 2045 ...
-
REDWOOD CITY, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced two significant developments...